A shorter-acting growth hormone booster that releases GH in natural pulses, mimicking what your body does on its own. Without the DAC attachment, it clears faster, so it's usually paired with another GH peptide for a stronger combined effect.
What to Expect
Week 1–2
Improved sleep quality, especially deeper sleep. Subtle increase in morning energy. GH pulses become more pronounced.
Week 3–6
Enhanced recovery between workouts. Mild fat loss beginning. Improved skin elasticity and hydration. Better overall sense of vitality.
Week 8+
Meaningful body composition changes. Connective tissue strengthening. Sustained energy improvements. Best results when combined with a GHRP like Ipamorelin.
Common Side Effects
Scientific Overview
Modified GRF (1-29), also known as CJC-1295 without DAC, is a truncated and modified analog of GHRH retaining residues 1–29 with substitutions at positions 2, 8, 15, and 27 to enhance receptor affinity and resist DPP-IV enzymatic degradation. Without the DAC moiety, its half-life is approximately 30 minutes, producing acute GH pulses rather than sustained elevation. This pulsatile pattern more closely mimics physiological GH secretion and is often combined with GH secretagogues like Ipamorelin for synergistic pituitary stimulation.
Dosing
100 mcg subq 2-3 times daily, ideally paired with a GH-releasing peptide like Ipamorelin. Cycle for 8-12 weeks.
Practical Guide
Reconstitution
Mix 2mg vial with 1mL BAC water. Typical dose is 100mcg (0.05mL) per injection.
Storage
Refrigerate after reconstitution. Use within 21-30 days. More fragile than DAC version.
Injection Sites
Subcutaneous with insulin syringe. Best combined with Ipamorelin in the same syringe for synergistic GH release.
Timing
Best injected 30 minutes before bed on empty stomach. Can also dose upon waking before breakfast. 2-3 times daily for aggressive protocols.
Food
Must inject on empty stomach — fats and carbs blunt GH release significantly. No food for 30 minutes post-injection.
Benefit Profile
Medical Considerations
Contraindications
- ✕Active cancer or pituitary tumors
- ✕Diabetic retinopathy
- ✕Pregnancy/nursing
- ✕Active acromegaly
Drug Interactions
Recommended Monitoring
- →IGF-1 levels every 3-6 months
- →Fasting glucose periodically
- →Monitor for carpal tunnel symptoms
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Clonidine pretreatment modifies the growth hormone secretory pattern induced by short-term continuous GRF infusion in normal man.
Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29.
Glycine-modified growth hormone secretagogues identified in seized doping material.
Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29).
New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.
Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.
The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I.
Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release.
Radiation and neuroregulatory control of growth hormone secretion.
Studies on alpha 2-adrenergic modulation of hypothalamic somatostatin secretion in rats.